What Has Been the Progress and Growth of the Vasomotor Menopausal Symptoms VMS Treatment Market in Recent Years?
The vasomotor menopausal symptoms vms treatment market has seen considerable growth due to a variety of factors.
• The market size for the treatment of vasomotor menopausal symptoms (VMS) has witnessed robust growth in the recent past. The market, valued at $17.86 billion in 2024, is expected to reach $19.19 billion in 2025, expanding at a compound annual growth rate (CAGR) of 7.5%.
Factors such as hormone replacement therapy (hrt), heightened awareness about menopause, advancements in pharmaceuticals, and consumer demand contribute to the growth observed in the historical period.
What Is The Expected Growth In The Vasomotor Menopausal Symptoms VMS Treatment Market Size Evolve over the Forecast Period?
The vasomotor menopausal symptoms vms treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for vasomotor menopausal symptoms (VMS) treatment is predicted to experience robust growth in the coming years. The market value is projected to reach $24.81 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.6%.
This anticipated growth during the forecast period is influenced by factors such as individualized medicine, innovations in non-hormonal treatments, interventions involving nutrition and diet, digital health and telemedicine. Key trends throughout the forecasted period include natural and alternative treatment methodologies, botanical and herbal remedies, the emergence of menopause support groups, and the application of cognitive behavioral therapy (cbt).
What Main Forces Are Fueling Expansion In The Vasomotor Menopausal Symptoms VMS Treatment Market?
The rise in the population of women going through menopause is expected to enhance the growth of the vasomotor menopausal symptom’s treatment market. Menopause is a natural occurrence that demarcates the conclusion of a woman's fertility period. Typically, it transpires between the ages of 45 and 55, with the median age being roughly 51. The growing population of women experiencing menopause, and the ensuing need for treatment to manage symptoms like hot flashes and vaginal dryness, is a major factor propelling the vasomotor menopausal symptoms (VMS) treatment market's growth. As an example, the Cuyuna Regional Medical Center in the US projected in November 2022 that 1.1 billion women would be menopausal by 2025, as life expectancy for women increases. Furthermore, the menopausal population is predicted to grow by 1.6% each year till 2060. Hence, the rise in the menopause population is fostering the growth of the vasomotor menopausal symptom’s treatment market. Government initiatives to improve women's health during menopause are expected to catalyze the growth of the vasomotor menopausal symptoms’ treatment market. These initiatives include funding for innovative studies on menopausal transition, preventing illnesses, and researching various pharmacological, clinical, and epidemiological elements of menopause. These actions are integrated parts of comprehensive women's health programs. In January 2023, the Government of New South Wales, an agency in Australia, initiated a $40.3 million investment spanning four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs for women suffering from severe menopausal symptoms. Therefore, government initiatives geared towards improving women's health during menopause are enhancing the growth of the vasomotor menopausal symptoms’ treatment market.
What Are The Primary Segments In The Global Vasomotor Menopausal Symptoms VMS Treatment Market?
The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines
Pre-Book The Vasomotor Menopausal Symptoms VMS Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Vasomotor Menopausal Symptoms VMS Treatment Market?
Key players in the treatment market for vasomotor menopausal symptoms are working on creating new treatments like Veozah, and securing necessary approvals to enhance treatment options and address the underserved medical needs in patients. The sanctioning of new medicines for menopause presents better efficiency and safety in relation to current treatments. For example, Astellas Pharma Inc, a pharmaceutical firm based in Japan, was granted approval by the Food and Drug Administration (FDA), a US federal unit, in May 2023 for Veozah (fezolinetant) 45 mg once daily for treating menopausal vasomotor symptoms (VMS), which can be mild to severe. This is the initial nonhormonal neurokinin 3 (NK3) receptor antagonist to be sanctioned for addressing VMS related to menopause. It is a hormone-free solution that impedes a brain pathway that aids in managing these symptoms, providing an alternative treatment for women dealing with these symptoms, particularly those who cannot or do not wish to use hormone therapy. The authorization of Veozah underscores its promise as a new medication for managing menopausal symptoms.
Who Are the Key Players In The Vasomotor Menopausal Symptoms VMS Treatment Market?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are:
• Pfizer Inc.
• Abbvie Inc.
• Novartis AG
• Ausio Pharmaceuticals LLC
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Kyowa Kirin Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Alembic Pharmaceuticals Limited Inc.
• Apotex Inc.
• Hikma Pharmaceutical PLC
• Endo Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC
• Mundipharma International Ltd.
• Lupin Limited
• Glenmark Pharmaceuticals Ltd.
• Hisamitsu Pharmaceutical Co. Inc.
• Zhejiang Huahai Pharmaceutical Co. Ltd.
• Emcure Pharmaceuticals Limited
• Wockhardt Pvt. Ltd.
• QuatRx Pharmaceuticals Company
• Bionovo Inc.
• Mithra Pharmaceuticals SA
• EndoCeutics Inc.
• Zydus Group
• Edgemont Pharmaceuticals LLC
• MenoGeniX Inc.
• Agile Therapeutics Inc.
What Is The Most Dominant Region In The Vasomotor Menopausal Symptoms VMS Treatment Market?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
